期刊
CELL CYCLE
卷 7, 期 8, 页码 965-970出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/cc.7.8.5753
关键词
T-cell lymphoblastic leukemia; notch1; PTEN; AKT; gamma-secretase inhibitor; oncogene addiction
类别
资金
- NCI NIH HHS [R01 CA120196, R01 CA120196-03, R01 CA129382-01A1, R01 CA129382] Funding Source: Medline
Activating mutations in NOTCH1 are the most prominent genetic abnormality in T-cell acute Lymphoblastic Leukemia ( T-ALL) and inhibition of NOTCH1 signaling with gamma- secretase inhibitors ( GSIs) has been proposed as targeted therapy in this disease. However, most T-ALL cell lines with mutations in NOTCH1 fail to respond to GSI therapy. Using gene expression profiling and mutation analysis we showed that mutational loss of PTEN is a common event in T-ALL and is associated with resistance to NOTCH inhibition. Furthermore, our studies revealed that NOTCH1 induces upregulation of the PI3K-AKT pathway via HES1, which negatively controls the expression of PTEN. This regulatory circuitry is evolutionary conserved from Drosophila to humans as demonstrated by the interaction of overexpression of Delta and Akt in a model of Notch-induced transformation in the fly eye. Loss of PTEN and constitutive activation of AKT in T-ALL induce increased glucose metabolism and bypass the requirement of NOTCH1 signaling to sustain cell growth. Importantly, PTEN-null/GSI resistant T-ALL cells switch their oncogene addiction from NOTCH1 to AKT and are highly sensitive to AKT inhibitors. These results should facilitate the development of molecular therapies targeting NOTCH1 and AKT for the treatment of T-ALL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据